Retrospective Prognostic Study of Death at Home or Hospice Versus at a Hospital Among Patients With Advanced Non-Small Cell Lung Cancer

被引:5
|
作者
Hamamoto, Yoichiro [1 ]
Ibe, Tatsuya [1 ]
Kodama, Hiroaki [1 ]
Mouri, Atsuto [2 ]
Mineshita, Masamichi [3 ]
机构
[1] Nishisaitama Chuo Natl Hosp, Dept Pulm Med, Tokorozawa, Saitama, Japan
[2] Saitama Med Univ, Dept Pulm Med, Int Med Ctr, Hidaka, Saitama, Japan
[3] St Marianna Univ, Dept Internal Med, Div Resp Med, Sch Med,Miyamae Ku, Kawasaki, Kanagawa, Japan
关键词
lung neoplasms; palliative care; hospices; inflammation; home care services; place of death; PALLIATIVE CARE; SURVIVAL; PLACE; ASSOCIATION;
D O I
10.1177/1049909119865865
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Patients with advanced non-small cell lung cancer greatly care about where they will die. Most people in Japan preferred their location of death as their homes. But only 8.2% of patients with cancer spend their last days at home with palliative care in Japan. Many patients with cancer are still going to spend their last days at a hospital (81.7%). Objective: We examined the survival times of such patients according to their place of death; that is, whether they died at home, at a hospice, or at a hospital, and investigated patient characteristics. Results: Among the 313 patients recruited, 214 were analyzed in this study: 90, 49, and 75 received hospital-based, home-based, and hospice-based palliative care, respectively. The patients who died at a hospice exhibited significantly longer survival than those who died at hospital (estimated median survival time, 420 days [95% confidence interval [CI]: 325-612 days] versus 252 days [95% CI: 201-316 days]; P < .0001). The characteristics of patients did not differ significantly according to place of death. Conclusions: Patients who died at a hospice or at home exhibited significantly longer survival than those who died at a hospital for advanced non-small cell lung cancer.
引用
收藏
页码:129 / 135
页数:7
相关论文
共 50 条
  • [41] CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients
    Ada, A. O.
    Kunak, S. C.
    Hancer, F.
    Bilgen, S.
    Suzen, S. H.
    Alpar, S.
    Gulhan, M.
    Kurt, B.
    Iscan, M.
    NEOPLASMA, 2010, 57 (06) : 512 - 521
  • [42] Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients
    Mezquita, Laura
    Charrier, Melinda
    Faivre, Laura
    Dupraz, Louise
    Lueza, Beranger
    Remon, Jordi
    Planchard, David
    Bluthgen, Maria Virginia
    Facchinetti, Francesco
    Rahal, Arslane
    Polo, Valentina
    Gazzah, Anas
    Caramella, Caroline
    Adam, Julien
    Pignon, Jean Pierre
    Soria, Jean-Charles
    Chaput, Nathalie
    Besse, Benjamin
    LUNG CANCER, 2017, 112 : 10 - 15
  • [43] Palliative care for patients with locally advanced and metastatic non-small cell lung cancer
    Simone, Charles B., II
    Jones, Joshua A.
    ANNALS OF PALLIATIVE MEDICINE, 2013, 2 (04) : 178 - 188
  • [44] Prognostic impact of prognostic nutritional index in advanced (stage IIIB/IV) non-small cell lung cancer patients
    Li, X. L.
    Yao, Z. H.
    Wan, Y. Y.
    Mou, X. Y.
    Ni, Y. H.
    Sun, E. L.
    Zang, D.
    Lin, D. J.
    NEOPLASMA, 2019, 66 (06) : 971 - 977
  • [45] Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review
    Jafri, Syed H.
    Shi, Runhua
    Mills, Glenn
    BMC CANCER, 2013, 13
  • [46] Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study
    Takayama, Koichi
    Atagi, Shinji
    Imamura, Fumio
    Tanaka, Hiroshi
    Minato, Koichi
    Harada, Toshiyuki
    Katakami, Nobuyuki
    Yokoyama, Takuma
    Yoshimori, Kozo
    Takiguchi, Yuichi
    Hataji, Osamu
    Takeda, Yuichiro
    Aoe, Keisuke
    Kim, Young Hak
    Yokota, Soichiro
    Tabeta, Hiroshi
    Tomii, Keisuke
    Ohashi, Yasuo
    Eguchi, Kenji
    Watanabe, Koshiro
    SUPPORTIVE CARE IN CANCER, 2016, 24 (08) : 3473 - 3480
  • [47] Early Incorporation to Palliative Care (EPC) in Patients With Advanced Non-Small Cell Lung Cancer: The PACO Randomized Clinical Trial
    Allende, Silvia
    Turcott, Jenny G.
    Verastegui, Emma
    Rodriguez-Mayoral, Oscar
    Flores-Estrada, Diana
    Camargo, Dana Aline Perez
    Ramos-Ramirez, Maritza
    Martinez-Hernandez, Jorge-Negueb
    Onate-Ocana, Luis F.
    Pina, Pamela Soberanis
    Cardona, Andres F.
    Arrieta, Oscar
    ONCOLOGIST, 2024, 29 (10) : e1373 - e1385
  • [48] Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non-small Cell Lung Cancer
    Lee, Jin Hwa
    Song, Eun Mi
    Sim, Yun Su
    Ryu, Yon Ju
    Chang, Jung Hyun
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (02) : 305 - 309
  • [49] Prognostic Significance of Telomerase Polymorphism in Non-Small Cell Lung Cancer
    Catarino, Raquel
    Araujo, Antonio
    Coelho, Ana
    Gomes, Monica
    Nogueira, Augusto
    Lopes, Carlos
    Medeiros, Rui M.
    CLINICAL CANCER RESEARCH, 2010, 16 (14) : 3706 - 3712
  • [50] Prognostic Significance of Initial Platelet Counts and Fibrinogen Level in Advanced Non-Small Cell Lung Cancer
    Kim, Kyung Hee
    Park, Tae Yun
    Lee, Ji Yeun
    Lee, Sang-Min
    Yim, Jae-Joon
    Yoo, Chul-Gyu
    Kim, Young Whan
    Han, Sung Koo
    Yang, Seok-Chul
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, 29 (04) : 507 - 511